

Generated Technical Summary (0-shot)

Generated Technical Summary (5-shot)

Target

The evidence suggests that Felbamate is an effective and safe add-on therapy for patients with drug-resistant focal epilepsy. The trial showed that Felbamate was superior to placebo in reducing seizures, with no major adverse events reported. Additionally, the data suggests that Felbamate may have an antiseizure effect when combined with lower levels of carbamazepine.

The evidence from these three studies suggests that felbamate is an effective and safe antiepileptic drug for refractory partial-onset seizures. It is well-tolerated by patients taking concomitant carbamazepine, and may reduce the need for higher doses of this medication. It is also associated with a decrease in seizure frequency, although further studies are needed to confirm this result.

In view of the methodological deficiencies, the limited number of included studies and the differences in outcome measures, we have found no reliable evidence to support the use of felbamate as an add-on therapy in people with drug-resistant focal-onset epilepsy. A large-scale, randomised controlled trial conducted over a longer period of time is required to inform clinical practice.

The evidence suggests that peri-implantation glucocorticoid administration does not provide a significant benefit to assisted reproductive technology cycles when it comes to improving pregnancy and implantation rates. While it may improve the pregnancy rate in patients with positive autoantibodies, it has not been shown to be effective in improving the overall outcome of IVF-ET cycles. Additionally, it has not been shown to be effective in reducing the risk of OHSS.

The evidence suggests that the use of low-dose glucocorticoids as an adjunct to IVF-ET does not have a significant effect on pregnancy or implantation rates, and does not reduce the incidence of ovarian hyperstimulation syndrome. Further research is needed to confirm these findings.

Overall, there was insufficient evidence that administration of peri-implantation glucocorticoids in IVF/ICSI cycles influenced clinical outcomes. These findings were limited to the routine use of glucocorticoids in subfertile women undergoing IVF or ICSI.

The evidence suggests that bioengineered nerve conduits and wraps are a safe and effective option for repair of transected peripheral nerves in the upper limb. They are comparable to conventional microsurgical techniques for repairing nerve lacerations, and for shorter nerve gaps, may provide superior results in terms of sensory recovery. Additionally, the use of a conduit eliminates the donor-site morbidity associated with nerve-graft harvesting.

The evidence suggests that nerve repair using a biodegradable poly(DL-lactide-epsilon-caprolactone) Neurolac nerve guide, a collagen nerve conduit, or a polyglycolic acid conduit can be as effective as conventional microsurgical techniques in repairing transected peripheral nerves in the hand. Furthermore, these methods can potentially reduce the occurrence of cold intolerance, and may be beneficial for repairing nerves with gaps of 4 mm or less. Further research is needed to confirm these findings.

Based on the available evidence, this review does not support use of currently available nerve repair devices over standard repair. There is significant heterogeneity in participants, injury pattern, repair timing, and outcome measures and their timing across studies of nerve repair using bioengineered devices, which make comparisons unreliable. [...] provide high-certainty evidence and facilitate more detailed analysis of effectiveness of emerging, increasingly sophisticated, bioengineered repair devices.